Insider Trading March 11, 2026

Director Purchases $100k of Solventum Stock After Q4 Results

Wendell Amy McBride adds 1,475 shares to a 5,039-share stake as Solventum posts modest revenue growth but misses EPS estimates

By Jordan Park SOLV
Director Purchases $100k of Solventum Stock After Q4 Results
SOLV

A director at Solventum Corp reported a purchase of 1,475 shares on March 10, 2026, according to a filed Form 4. The acquisition, priced at $68.03 per share and totaling roughly $100,344, increases the director's direct holdings to 5,039 shares. The transaction comes amid mixed quarterly results and an analyst reiteration of an Overweight rating.

Key Points

  • Director Wendell Amy McBride purchased 1,475 shares of Solventum on March 10, 2026, at $68.03 per share, totaling about $100,344.
  • After the purchase McBride owns 5,039 shares directly; the stock was trading at $67.60 and is down nearly 15% year-to-date with a P/E of 7.97.
  • Solventum reported Q4 revenue of $2.0 billion (3.5% organic growth) and EPS of $1.57, below the forecasted $1.75; Piper Sandler reiterated an Overweight rating with a $98.00 target.

A Solventum Corp (NYSE:SOLV) director, Wendell Amy McBride, bought 1,475 shares of the company's stock on March 10, 2026, a Form 4 filing with the Securities and Exchange Commission shows. The shares were acquired at $68.03 apiece, bringing the transaction value to approximately $100,344.

Following the purchase, McBride directly holds 5,039 shares of Solventum. At the time the data was reported, the stock was trading at $67.60 and was down nearly 15% year-to-date, with a price-to-earnings ratio of 7.97.


Recent company financials provide context for the insider activity. Solventum disclosed fourth-quarter revenue of $2.0 billion, reflecting organic growth of 3.5%. Reported earnings per share were $1.57, which missed the consensus forecast of $1.75.

Market research and advisory activity noted in the filings and disclosures includes an analyst action from Piper Sandler, which reiterated an Overweight rating on Solventum and maintained a $98.00 price target. The firm highlighted the companys ongoing revenue growth and its performance record since the initial public offering.

Additionally, third-party platform analysis identifies Solventum as appearing undervalued at current levels. According to InvestingPro analysis, the stock is listed on the platforms Most Undervalued list, and users can access further insight via seven additional InvestingPro Tips and a comprehensive Fair Value analysis on that service.

The filing and the earnings disclosure together create a snapshot of insider sentiment and recent operational results. The director purchase is a concrete transaction recorded with regulators, while the quarterly results show revenue expansion alongside an earnings shortfall versus estimates. Piper Sandlers maintained positive recommendation and price target are noted in the company's recent financial communications.

Risks

  • Earnings shortfall: Solventums Q4 EPS of $1.57 missed the forecasted $1.75, indicating potential near-term earnings pressure that could affect investor sentiment - impacts equity markets and investor allocations.
  • Share-price volatility: The stock is down nearly 15% year-to-date and trades at a relatively low P/E of 7.97, which reflects market uncertainty and could lead to further price swings - impacts equity investors and market stability for the ticker.
  • Limited disclosure on drivers: While revenue growth and analyst commentary are reported, the available information does not fully explain the EPS miss or future guidance, leaving uncertainty for analysts and shareholders - impacts financial analysts and investor decision-making.

More from Insider Trading

Indivior Director Adds to Stake as Shares Hover Near Fair Value Mar 11, 2026 Jared Isaacman Buys $2.0M of Shift4 Payments Stock Amid Strategic Moves Mar 11, 2026 SBC Medical CEO Disposes $9.38M in Shares as Company Pursues Growth Moves Mar 10, 2026 Antero Midstream Accounting Chief Disposes $318,640 in Shares; Retains Majority Stake Mar 10, 2026 Hinge Health Executive Chairman Sells $7.5M in Class A Shares and Converts Class B Stock Mar 10, 2026